HARVARD BIOSCIENCE INC
Harvard Bioscience develops, manufactures and sells life science products and services for research, drug and therapy discovery, bioproduction and preclinical testing. Its customers include academic and government laboratories, pharmaceutical and biotechnology companies, hospitals and contract research organizations. The company sells globally through direct sales and distributors and is headquartered in Holliston, Massachusetts. Harvard Bioscience organizes its products into Cellular and Molecular and Preclinical families. Cellular and Molecular products support molecular, cellular, organ and organoid research, with brands including Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner. Preclinical products support drug research and testing, including telemetry, behavioral monitoring, respiratory systems and data acquisition and analysis; brands include DSI, Panlab, Hugo Sachs and Buxco. Products include instruments, software, consumables and services. The company also distributes products made by other manufacturers.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $HBIO in the last 30 days.
See all $HBIO insider activity →Harvard Bioscience (HBIO) reported Q3 2026 revenue of $22.2M, up 8% YoY, driven by Asia-Pacific demand. Gross margins compressed to 55.4% from 59.2% YoY due to product mix shifts. Operating loss widened to $1.2M. The company expects Q4 revenue of $23.7M-$25.5M and improved margins. Shares traded at $9.12 premarket.
Harvard Bioscience (HBIO) reported Q3 EPS of -$0.06, beating estimates by $0.21, with revenue of $22.2M, exceeding expectations. The stock is up 36.59% in 3 months and 49.63% in 12 months, with a 'fair performance' financial health score according to InvestingPro.
HARVARD BIOSCIENCE INC (HBIO) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 NASDAQ: HBIO Harvard Bioscience Investor Overview November 202 6 Forward - Looking Statements This document contains forward - looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995 . Forwa
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning HBIO (HARVARD BIOSCIENCE INC). Coverage has skewed bearish: 1 bullish, 3 neutral, and 2 bearish.
Recent HBIO coverage spans earnings, market movers and financial news.
Revenue rose but profitability fell and guidance was reduced, likely weighing on the stock.
Earnings beat may lift the stock as investors reassess profitability.
The new guidance suggests modest revenue growth and margin expansion, which may support a slight price appreciation.
The company posted Q3 revenue up 8% YoY to $22.2M but widened net loss, and reaffirmed modest growth guidance.
Guidance is modestly positive on growth but mixed on profitability, with margin pressure from product and geographic mix shifts.
AlphAI scores every news story that mentions HBIO with an AI model for sentiment and relevance, and aggregates insider trades from HARVARD BIOSCIENCE INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Harvard Bioscience (HBIO) reported Q3 2026 revenue of $22.2M, up 8% YoY, driven by Asia-Pacific demand. Gross margins compressed to 55.4% from 59.2% YoY due to product mix shifts. Operating loss widened to $1.2M. The company expects Q4 revenue of $23.7M-$25.5M and improved margins. Shares traded at $9.12 premarket.
Harvard Bioscience (HBIO) reported Q3 EPS of -$0.06, beating estimates by $0.21, with revenue of $22.2M, exceeding expectations. The stock is up 36.59% in 3 months and 49.63% in 12 months, with a 'fair performance' financial health score according to InvestingPro.
HARVARD BIOSCIENCE INC (HBIO) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 NASDAQ: HBIO Harvard Bioscience Investor Overview November 202 6 Forward - Looking Statements This document contains forward - looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995 . Forwa
HARVARD BIOSCIENCE INC (HBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2026 Financial Results · Third Quarter 2026 Revenue Growth of 8% Year Over Year to $22.2 Million · Reaffirms Full Year 2026 Revenue Guidance of 3%-5% Year Over Year Growth HOLLISTON, Mass., November 10, 2026 (GLOBE NEWSWIRE)
Harvard Bioscience (HBIO) reported Q2 2026 revenue of $22.7M, up 11%, and adjusted EBITDA of $1.7M, up 11%. Full-year revenue guidance was raised to 3-5% growth, but gross margin guidance was lowered to 57-59% due to product and geographic mix shifts. The company expects $3M in cost savings from Project Viking in 2027. Americas and APAC regions showed strong growth, while Europe grew modestly. Adjusted EPS was -$0.14, and Q3 revenue guidance is $21.0M-$22.6M.
Harvard Bioscience (HBIO) reported Q2 2026 revenue up 11%, driven by CRO demand and double-digit growth in telemetry and CMT portfolios. China sales rose on its “Made in China” BTX line. Recurring revenue reached 55%. Full-year guidance raised to 3% to 5% growth, but adjusted gross margin cut 100 bps to 57% to 59%, with Project Viking cost savings.
Benchmark raised its price target for Harvard Bioscience (NASDAQ:HBIO) to $7.50 from $6.00 and kept a Speculative Buy rating after Q2 results. Q2 revenue was $22.7M, above guidance and consensus. Full-year 2026 revenue growth guidance was lifted to 3% to 5%. Adjusted gross margin target was lowered to 57% to 59%.
Harvard Bioscience (HBIO) reported Q2 revenue of $22.7 million, up 11% year over year, with gross profit $12.6 million and gross margin 55.6%. Adjusted EBITDA rose to $1.7 million. The company raised FY2026 revenue growth guidance to 3%-5% and expects Q3 2026 revenue of $21.0 million to $22.6 million.
HARVARD BIOSCIENCE INC (HBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Harvard Bioscience Announces Second Quarter 2026 Financial Results · Second Quarter 2026 Revenue Growth of 11% Year Over Year to $22.7 Million · Raises Full Year 2026 Revenue Guidance to 3%-5% Year Over Year Growth HOLLISTON, Mass., August 11, 2026 (GLOBE NEWSWIRE) -
The article reports on the discontinued operations of Harvard Bioscience, Inc., traded on the Frankfurt Stock Exchange under the symbol HBI0. It appears to be a financial news brief, likely indicating a change in the company's operational status. The content is brief and serves as a notification regarding this financial event.
